Natriuretic peptides (ANP, BNP, CNP) function as multi-system regulators beyond simple heart stress markers, with therapeutic potential across heart failure, kidney disease, and metabolic conditions when their signaling is enhanced.
Beyond biomarkersNatriuretic peptides regulate cardiovascular, renal, metabolic, and immune pathways—but resistance mechanisms limit their therapeutic potential in advanced disease
What the researchers found
Natriuretic peptides act as multisystem regulators with natriuretic, vasodilatory, antifibrotic, and immunomodulatory effects via cGMP-PKG signaling, but their therapeutic potential is limited by NP resistance mechanisms including neprilysin degradation, NPR-C clearance, and receptor desensitization in advanced disease.
Why it matters
Understanding natriuretic peptides as therapeutic targets rather than just diagnostic markers could unlock new treatment strategies for heart failure, obesity-related cardiovascular disease, and immune-cardiometabolic syndromes. Overcoming NP resistance is key to realizing this potential.
The numbers in context
Reviews PARADIGM-HF, PARAGON-HF, and EMPEROR-Preserved trial data. Discusses ARNIs, designer peptides, NPR-C modulation, and receptor sensitizers as therapeutic approaches.
How the study worked
Narrative review integrating human physiology, preclinical studies, and major clinical trials (PARADIGM-HF, PARAGON-HF, EMPEROR-Preserved), plus analysis of emerging therapeutic agents.
Who was studied
Not applicable (review of natriuretic peptide biology and therapeutics)
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. Many of the proposed therapeutic strategies remain preclinical or in early-phase trials. The translational roadmap proposed is largely theoretical and requires validation.
How to read the evidence
Narrative review synthesizing major clinical trials (PARADIGM-HF demonstrated clear benefit of ARNIs in HFrEF) and preclinical evidence. Well-sourced but not a systematic analysis.
When this study was published
Published in 2025; incorporates the latest clinical trial data and emerging therapeutic strategies for NP augmentation.
The bigger picture
Natriuretic peptides sit at the intersection of cardiology, immunology, and metabolism—three fields increasingly recognized as interconnected. This review frames peptide-based therapies as a bridge across these disciplines, with implications for personalized medicine approaches based on patient phenotyping.
Questions still open
- Can designer natriuretic peptides overcome resistance mechanisms more effectively than current ARNIs?
- Which patient phenotypes are most likely to benefit from NP augmentation therapy?
- How might combining NP-based therapies with SGLT2 inhibitors improve outcomes in obesity-related HFpEF?
Common questions
What are natriuretic peptides and why are they important?
What is NP resistance and why does it matter?
Read the original research
Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.
Cardiovascular drugs and therapy
Citation
Panneflek, Jathniel; Barbarawi, Mahmoud; Kakarlapudi, Yasitha; Barbarawi, Zaid; Lauzea, Béatrice; Meraz-Torres, Manolo. (2025). Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.. Cardiovascular drugs and therapy. https://doi.org/10.1007/s10557-025-07821-y